Skip to main content

Genitourinary: DAD-IO

Trial ID
04724018
Trial Sponsor
Dana Farber Cancer Institute

Combinations of Sacituzumab govitecan plus enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma: the Double Antibody Drug conjugate (DAD) and Double Antibody Drug Conjugate with Immunotherapy Phase I/II trial

Is your health insurance changing in 2026? Be sure to bring your new card in for our records!

X